Immunohistochemical profile and clinical-pathological variables in breast cancer  by Duarte Cintra, Jane Rocha et al.
ORIGINAL ARTICLE
SUMMARY
Objective: To describe the main characteristics of women with breast cancer, accord-
ing to the immunohistochemical profile. Methods: The population comprised a hospi-
tal cohort, consisting of women diagnosed with breast cancer between 2003 and 2005 
(n = 601) and treated at a referral center for cancer care in Juiz de Fora, MG, Brazil. Only 
397 women who had complete immunohistochemistry analysis were selected. To define 
the groups according to the immunohistochemical profile, the assessment of estrogen 
and progesterone receptors, Ki-67 cell proliferation index, and overexpression of hu-
man epidermal growth factor receptor 2 (HER2) was chosen. According to the different 
phenotypes, five subtypes were defined: luminal A, luminal B HER2 negative, luminal B 
HER2 positive, triple negative, and HER2 overexpression. Results: Most patients were 
white (80.7%) and post-menopausal (64.9%), with a mean age of 57.4 years (± 13.5). 
At diagnosis, 57.5% had tumor size ≥ 2.0 cm, and 41.7% had lymph node involvement. 
The most common subtypes were luminal B - HER2 negative (41.8%) and triple negative 
(24.2%). In the luminal A subtype, 72.1% of patients were post-menopausal, while the 
highest percentage of premenopausal women were observed in the luminal B - HER2 
positive and triple negative subtypes (45.2% and 44.2%, respectively). A higher frequen-
cy of tumors > 2.0 cm and lymph node involvement was observed in triple negative and 
HER2 positive subtypes. Conclusion: This study allowed the distribution assessment of 
the main clinical and pathological characteristics and those related to health services in 
a cohort of Brazilian women with breast cancer, according to the immunohistochemical 
tumor subtypes.
Keywords: Progesterone receptors; erbB2 receptor; breast neoplasias; immunohisto-
chemistry; estrogen receptors; Ki-67 antigen.
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INTRODUCTION
Breast cancer is the neoplasia with the highest incidence 
in the female population worldwide1-3. Regarding mor-
tality, this neoplasia represented approximately 13.7% of 
all deaths caused by cancer worldwide in 2008, except for 
non-melanoma skin tumors2. In the U.S. population, there 
was a 12.3% reduction in mortality rates due to breast can-
cer between the years 1991 and 2006, which was mainly 
attributed to the expansion of mammographic screening4. 
In Brazil, approximately 49,240 new cases of breast 
cancer were estimated in 20105. Based on data from cancer 
registries of the national population basis, the incidence of 
the disease is similar to that observed in developed coun-
tries6,7. It is the leading cause of female death by cancer 
in the country8,9, with an estimated 11,735 deaths due to 
the disease in 20085. According to the Health Surveillance 
Secretariat, the female population at greatest risk of illness 
is between the ages of 50 and 69 years. However, there are 
still significant limitations for these women to have access 
to secondary preventive measures related to this type of 
cancer10.
Tumor heterogeneity of breast cancer is one of the big-
gest challenges to be faced, considering that tumors with 
the same histological types, stages, and degrees of differen-
tiation may have different outcomes in relation to prognos-
tic factors and responses to implemented treatments11,12. 
It has been observed that, for better understanding and 
characterization of breast tumors, the currently used tra-
ditional classification has proved to be insu cient12. A 
comprehensive approach is required, including the mor-
phological characteristics; evaluation of tumor aggressive-
ness, with special reference to histological type; presence 
of inammatory response; number of mitoses; nuclear 
polymorphism; and vascular and lymphatic endothelial 
involvement13-15. It is believed that the differences demon-
strated in the biological behavior of microscopically simi-
lar tumors can be justified by the complexity of breast can-
cer and by the accumulation of molecular alterations15,16. 
The advances made in molecular biology techniques 
have provided better understanding of the mechanisms 
that regulate cell differentiation and proliferation17,18. Ac-
cumulation of mutations, genetic alterations, and chro-
mosomal instabilities that stimulate proliferation and cell 
damage continuously impair the system of growth regu-
lation and apoptosis, and cause the appearance of cancer. 
These factors have oen been recognized and new predic-
tive and prognostic biomarkers have been tested in tumor 
samples, through immunohistochemical analysis11,19.  
The expression of hormone receptors (estrogen re-
ceptors - ER, and progesterone receptors - PR), as well 
as overexpression or amplification of the human epider-
mal growth factor receptor 2 (HER2) have been identi-
fied as important predictors among patients with breast 
cancer20,21. Currently, these markers are commonly used to 
define treatment and establish disease prognosis associat-
ed with clinical and pathological variables, such as lymph 
node involvement, tumor size, histological type, tumor 
grade, and surgical margins22,23.
Approximately two-thirds of breast tumors express 
activation for ER and PR in the tumor core and thus are 
candidates for antiestrogen therapy24. Another 20% have 
HER2 amplification and may benefit from trastuzumab-
directed targeted therapy, which is a monoclonal antibody 
that may be used alone or in combination with chemother-
apy, reducing the risk of relapse by 50%, when used as an 
adjuvant treatment25-27. 
With a better understanding of the structure of the 
human DNA sequence and the development of high-tech 
methods such as cDNA microarrays, major changes in 
cancer-related research have been possible28. Several stud-
ies are already using this technique for DNA sequencing to 
better understand the great diversity found among histo-
logically similar tumors29. 
The definition according to the immunohistochemi-
cal profile is based on the evaluation of ER and PR, HER2 
overexpression, and the Ki-67 cell proliferation index (a 
monoclonal antibody that detects a nuclear antigen, ex-
pressing cells entering the cell cycle and measuring the 
cell growth fraction)30-33. According to the different phe-
notypes obtained, five subtypes are currently defined: 
luminal A (ER+, PR+, HER2-), luminal B HER2 nega-
tive (ER+ and/or PR+, HER2-), luminal B HER2 positive 
(ER+ and/or PR+, HER2+), triple negative (ER-, PR-, HER2-) 
and HER2 (ER-, PR-, HER2+)30. Luminal tumors have 
been associated with a more favorable prognosis, while 
triple-negative subtypes and HER2 overexpression, with 
a less favorable prognosis34,35. Triple negative tumors have 
a higher risk of recurrence within three years and higher 
mortality rates within five years, when compared to other 
subgroups36,37.  
Considering the current implications of the therapeu-
tic approach for breast cancer, studies that provide a bet-
ter understanding of the selection of the most appropriate 
markers to be used in clinical practice in Brazil should be 
encouraged, as well as a better understanding of the dis-
ease distribution in Brazilian women. This study aimed 
to evaluate the distribution of the main characteristics in 
women with breast cancer according to the hormone re-
ceptor profile (ER and PR), HER2 expression, and Ki-67 
proliferation index, by immunohistochemical analysis.
METHODS
STUDY POPULATION
The study population consisted of a hospital-based cohort 
comprising women diagnosed with breast cancer between 
January 2003 and December 2005 (n = 601) treated at a 
JANE ROCHA DUARTE CINTRA ET AL.
180 Rev Assoc Med Bras 2012; 58(2):178-187
referral center for cancer care in the city of Juiz de Fora, 
state of Minas Gerais, Brazil. The immunohistochemical 
profile analysis showed that 89 cases had an incomplete 
profile (absent HER2 and/or Ki-67), and 115 cases did not 
display such information in the medical files; therefore, 
only women who had a complete immunohistochemical 
panel were selected for this study (n = 397).
DATA COLLECTION AND STUDY VARIABLES 
The recruitment of cases was performed from the can-
cer registry of the aforementioned hospital-based refer-
ral center. Data were collected through an active search 
of medical records, in order to collect information from 
previously identified patients using a standardized form.
The immunohistochemical profiling of tumors was 
performed based on the results of reports issued by pa-
thology services with renowned technical quality, based 
on the evaluation of ER and PR, HER2 overexpression, 
and Ki-67 proliferation index. According to the different 
phenotypes obtained, five immunohistochemical sub-
types were defined: luminal A (ER+, PR+, HER2-), lumi- 
nal B HER2 negative (ER+ and/or PR+, HER2-), luminal 
B HER2-positive (ER+ and/or PR+, HER2+), triple 
negative or basal (ER-, PR-, HER2-), and HER2 over-
expression (ER-, PR-, HER2+)30. According to the 2011 
St. Gallen Consensus, the Ki-67 index is considered 
low or negative when < 14%, and positive or high when 
≥ 14%29. In the study population, however, this marker 
was scored as null (no immunostaining), low (10% or 
less immunopositivity), or high (> 10% immunoreactive 
cells), based on the criteria adopted at the time of diag-
nosis of the cases38. For this study, the Ki-67 index was 
considered low for cases with an immunopositivity value 
< 10%, and high for those with values ≥ 10%.  
The following variables were analyzed: date of diag-
nosis; age at diagnosis (in years) categorized as: up to 39, 
40-49, 50-69, and ≥ 70 years, dichotomized as  50, and 
> 50 (cutoff validated as a marker for menopausal sta-
tus)39; ethnicity (classified as white or non-white). Vari-
ables related to healthcare services were: the nature of the 
oncology service (public, or private); presence of private 
health insurance; type of surgery (curative or diagnostic 
only, excisional biopsy, or lumpectomy without lymph 
node approach); additional therapy (radiotherapy, che-
motherapy, or hormone therapy). Tumor characteristics 
were: tumor size (categorized as:  2.0 cm and > 2.0 cm); 
histological type; lymph node involvement; staging ac-
cording to TNM classification of the Union for Interna-
tional Cancer Control (UICC)40; and presence of metas-
tases (locoregional or systemic; at diagnosis and during 
the course of the disease - the latter obtained by informa-
tion collected at the time of data collection carried out 
in 2010).
DATA ANALYSIS
EPI INFO, release 3.5.3 (2011), was used for data entry and 
analysis. The differences in the distribution of the study 
variables were evaluated by the chi-square test (2) and, 
when necessary, by Fisher’s exact test (SPSS 8.0), consider-
ing statistically significant when p-value < 0.05. The study 
design was approved by the Ethics Committee of Universi-
dade Federal de Juiz de Fora - protocol No. 042/2008. 
RESULTS
According to the immunohistochemical profile, the study 
population was distributed in the following subtypes: lu-
minal A: 17.1%; luminal B, HER2 negative: 41.8%; lumi-
nal B, HER2 positive: 10.8%; HER2 overexpression : 6.0%; 
and triple negative: 24.2%. The predominant histological 
type was infiltrating ductal (73.3%), followed by infiltrat-
ing lobular (9.8%), and other histological variants (8.6%), 
with 7.0% of the cases represented by in situ carcinoma. 
The distribution of the main clinical characteristics ac-
cording to breast cancer subtypes classified by immunohis-
tochemistry is shown in Table 1. The mean age at diagnosis 
was 57.4 years (range 26-91 years), with a median of 58.0 
years (25th percentile: 46.0, and 75th percentile: 67.0), and 
73% of these were between 40 and 69 years. Only 27 women 
(6.9%) were younger than 39 years. Among patients with 
HER2 overexpression, two peaks of higher frequency of cas-
es were identified: between 40 and 59, and 70 years or more.
Most women were white (80.7%), with a higher per-
centage of non-white in the triple negative subtype 
(39.7%), and white in the luminal B HER2 negative sub-
type (45.4%) (p = 0.02).
The age dichotomized for the characterization of 
menopausal status showed that 64.9% of patients were 
postmenopausal. For the luminal A subtype, it was ob-
served that 72.1% of patients were postmenopausal, 
whereas luminal B HER2 positive and triple negative sub-
types showed the highest percentages of premenopausal 
women (45.2% and 44.2% respectively, p = 0.07). 
The pathological features according to the subtypes 
considered are shown in Table 2. At diagnosis, 57.5% of 
patients had tumors > 2.0 cm, and 41.7% had lymph node 
involvement. The highest percentages of tumors > 2.0 cm 
were observed in HER2 overexpression, luminal B HER 
positive, and triple negative subtypes (78.9%, 70.0% and 
60.6%, respectively), whereas among the luminal A sub-
type, tumor size  2.0 cm was observed in 58.7% of cases 
(p = 0.009). It is noteworthy that the highest percentages of 
tumors > 5 cm were found in luminal B HER2 positive and 
triple negative subtypes (17.5% and 13.8% respectively, 
p = 0.03 - data not shown).  
Among the subgroups involved with higher frequen-
cy of lymph node involvement, luminal B HER2 positive 
(53.8%), triple negative (48.9%), and HER2 overexpression 
IMMUNOHISTOCHEMICAL PROFILE AND CLINICAL-PATHOLOGICAL VARIABLES IN BREAST CANCER
181Rev Assoc Med Bras 2011; 58(2):178-187
(40.9%) were noteworthy, whereas luminal A showed the 
lowest percentage (12.3%) (p = 0.05). A higher frequency 
of tumors > 2.0 cm and lymph node involvement was ob-
served in triple negative, luminal B HER2 positive, and 
HER2 overexpression subtypes.
For the luminal A subtype, 92% of tumors showed 
early stage disease (in situ: 7.9%, I: 44.4%, II: 39.7%), while 
for the other subgroups, there were higher percentages in 
stages II and III (luminal B HER2 positive: 72.1%; triple 
negative: 71.2%, HER2 overexpression: 63.6%, luminal B 
HER2 negative: 61.5%). At diagnosis, an increased fre-
quency of disease in stage IV was identified for the HER2 
overexpression subtype (9.1%). Regarding menopausal 
status, there were higher percentages of cases at early 
stages in postmenopausal women (in situ: 73.9%, I: 72.1%, 
II: 63.6%), while premenopausal women exhibited higher 
rates of advanced disease (III and IV: 48.8% and 21.4%, 
respectively, p = 0.02 - data not shown). 
Metastatic disease at diagnosis was demonstrated in 
15 women (4.6%), some with more than one metastatic 
site involved, and the most common sites were: bone 
(70.5%), liver (23.5%), and lung (17.6%). During the 
course of the disease, 15.9% of patients (n = 63) devel-
oped systemic dissemination. Among the subtypes more 
Table 1 – Distribution of clinical characteristics according to subtypes of breast cancer classiﬁed by immunohistochemical analysis
Characteristics Luminal A
Luminal 
B-HER2 
negative
Luminal 
B-HER2 
positive
HER2
Triple 
negative
Total cases 
and %
p-value
Race* 0.02
White 50 129 28 17 60 284  
Line % 17.6 45.4 9.9 6.0 21.1 100  
Col % 89.3 84.9 77.8 81.0 69.0 80.7  
Non-white 6 23 8 4 27 68  
Line % 8.8 33.8 11.8 5.9 39.7 100  
Col % 10.7 15.1 22.2 19.0 31.0 19.3  
Age at diagnosis# 0.5
< 40 2 14 6 1 4 27  
Line % 7.4 51.9 22.2 3.7 14.8 100  
Col % 2.9 8.5 14.3 4.2 4.2 6.9  
40-49 16 36 11 6 34 103  
Line % 15.5 35.0 10.7 5.8 33.0 100  
Col % 23.5 22.0 26.2 25.0 35.8 26.2  
50-59 15 38 7 6 19 85  
Line % 17.6 44.7 8.2 7.1 22.4 100  
Col % 22.1 23.2 16.7 25.0 20.0 21.6  
60-69 21 44 8 5 21 99  
Line % 21.2 44.4 8.1 5.1 21.2 100  
Col % 30.9 26.8 19.0 20.8 22.1 25.2  
≥ 70 14 32 10 6 17 79  
Line % 17.7 40.5 12.7 7.6 21.5 100  
Col % 20.6 19.5 23.8 25.0 17.9 20.1  
Menopausal status* 0.07
Post-menopausal 49 113 23 17 53 255  
Line % 19.2 44.3 9.0 6.7 20.8 100  
Col % 72.1 68.9 54.8 70.8 55.8 64.9  
Pre-menopausal 19 51 19 7 42 138  
Line % 13.8 37.0 13.8 5.1 30.4 100  
Col % 27.9 31.1 45.2 29.2 44.2 35.1  
*χ2 Test; #Fisher’s Test. Total cases of each variable may differ due to the occurrence of ignored data.
JANE ROCHA DUARTE CINTRA ET AL.
182 Rev Assoc Med Bras 2012; 58(2):178-187
involved with increased morbidity, the most important 
were: HER2 overexpression (50.0%), and triple negative 
(48.0%), compared to luminal A (13.8%) and luminal 
B HER2 positive (19.2%) subtypes, and the latter two 
were related to lower incidence of distant metastases 
(p = 0.004 - data not shown). 
Table 2 – Distribution of pathological characteristics according to subtypes of breast cancer classiﬁed by immunohistochemical 
analysis
Characteristics Luminal A
Luminal 
B-HER2 
negative
Luminal 
B-HER2 
positive
HER2
Triple 
negative
Total cases 
and %
p-value
Tumor size# 0.009
≤ 2.0 cm 37 68 12 4 37 158  
Line % 23.4 43.0 7.6 2.5 23.4 100  
Col % 58.7 43.6 30.0 21.1 39.4 42.5  
> 2.0 cm 26 88 28 15 57 214  
Line % 12.1 41.1 13.1 7.0 26.6 100  
Col % 41.3 56.4 70.0 78.9 60.6 57.5  
Lymph nodes* 0.05
Negative 48 90 18 13 46 215  
Line % 22.3 41.9 8.4 6.0 21.4 100  
Col % 71.6 59.6 46.2 59.1 51.1 58.3  
Positive 19 61 21 9 44 154  
Line % 12.3 39.6 13.6 5.8 28.6 100  
Col % 28.4 40.4 53.8 40.9 48.9 41.7  
Metastases (at diagnosis and 
during the course of the disease)*
    0.0005
Absent 62 139 38 14 69 322  
Line % 19.3 43.2 11.8 4.3 21.4 100  
Col % 91.2 83.7 88.4 58.3 71.9 81.1  
Present 6 27 5 10 27 75  
Line % 8.0 36.0 6.7 13.3 36.0 100  
Col % 8.8 16.3 11.6 41.7 28.1 18.9  
Staging#         0.001
In situ 5 11 3 3 1 23  
Line % 21.7 47.8 13.0 13.0 4.3 100  
Col % 7.9 7.1 7.0 13.6 1.1 6.1  
I 28 43 8 3 23 105  
Line % 26.7 41.0 7.6 2.9 21.9 100  
Col % 44.4 27.6 18.6 13.6 24.5 27.8  
II 25 67 17 11 35 155  
Line % 16.1 43.2 11.0 7.1 22.6 100  
Col % 39.7 42.9 39.5 50.0 37.2 41.0  
III 3 29 14 3 32 81  
Line % 3.7 35.8 17.3 3.7 39.5 100  
Col % 4.8 18.6 32.6 13.6 34.0 21.4  
IV 2 6 1 2 3 14  
Line % 14.3 42.9 7.1 14.3 21.4 100  
Col % 3.2 3.8 2.3 9.1 3.2 3.7  
#Fisher’s Test; *χ2 Test. Total cases of each variable may differ due to the occurrence of ignored data.
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Among the 16 (7.3%) women who had local and re-
gional disease recurrence, the HER2 positive and triple 
negative subtypes were also responsible for the highest 
percentage (14.3% and 12.2%, respectively), whereas in 
the luminal A subtype only one patient was identified 
with local recurrence. There was no significant difference 
in the distribution of metastases (at diagnosis and during 
the course of disease) in the study population, according 
to the nature of the health service (public versus private 
- data not shown).  
The distribution of characteristics related to the use of 
health services is shown in Table 3. The highest percent-
age of cancer patients used the private healthcare system 
(56.4%). Among the HER2 overexpression, luminal B 
HER2 negative, and luminal A subtypes, most patients 
were treated by private healthcare services (83.3%, 59.0% 
and 54.4%, respectively), whereas patients with luminal 
B HER2 positive and triple negative subtypes showed to 
be evenly distributed between the public health system 
(Sistema Único de Saúde – SUS) and private healthcare 
services (p = 0.03). Among the women treated by the 
public health service, 5.6% had healthcare insurance.  
Most women underwent surgery with curative intent 
(93.8%). A higher percentage of curative surgery among 
patients with stage I (99.0%), II (92.9%) and III (97.4%), 
and diagnostic surgery among those with stage IV (53.8 %) 
(p = 0.000) was observed, with no statistically significant 
difference in the distribution of cases regarding the indi-
cation for surgery (curative or diagnostic), according to 
established immunohistochemical subtypes. With regard 
to systemic treatment (chemotherapy and /or hormone 
therapy), 95.1% of the patients received some type of 
therapeutic approach, with 60.6% receiving chemothera-
py (n = 238), and 60.3% hormone therapy (n = 237). 
Extensive use of hormone therapy was observed 
among patients with luminal subtypes (A: 88.2%; B HER2 
negative: 84.8%; and B HER2 positive: 76.7%), whereas 
this use was minimal among HER2 overexpression and 
triple negative subtypes (0.4% and 1.7%, respectively) 
(p = 0.000). Among the subtypes, there was a higher per-
centage of chemotherapy use with triple negative (78.7%) 
and HER2 overexpression (70.8%), whereas among cases 
of luminal A subtype, only 36.8% of cases  used this ther-
apy (p = 0.000).
Among the cases of luminal B HER2 positive sub-
group, 34.9% of patients did not use chemotherapy. 
Radiotherapy was used in 80.9% of patients, especially 
among those who had HER2 overexpression subtypes 
(95.0%) and luminal B HER2 positive (90.0%), who were 
in the subgroups with more advanced disease at diag-
nosis (tumors> 2.0 cm and lymph node involvement), 
compared with those who did not receive this therapy 
(p = 0.01).  
DISCUSSION AND CONCLUSION
This study identified the distribution of immunohisto-
chemical subtypes in patients with breast cancer who un-
derwent treatment in public and private healthcare institu-
tions of a medium-sized city, a macro-regional reference 
center for cancer care in Southeastern Brazil. According 
to this profile, the immunohistochemical subtypes with 
higher frequencies were luminal B HER2 negative (41.8%) 
and triple negative (24.2%). This finding differs from that 
observed in a study of 10,159 women, based on data from 
12 cancer registries and a hospital-based population of 
several countries (North America, Europe, and Australia), 
with a case reporting period from 1974 to 2005, which 
demonstrated that luminal A was the most frequent sub-
type, with a percentage of approximately 71.3%, followed 
by triple negative (16%)41. 
The latter study did not include the evaluation of the 
Ki-67 cell proliferation index, and instead considered oth-
er markers for classification of subtypes, such as epidermal 
growth factor receptor (EGFR) and cytokeratin 5 and/or 6. 
In the present study, however, the classification proposed 
by the St. Gallen Consensus (2011) was considered, which 
stratified the tumors as luminal A, B HER2 negative, and 
B HER2 positive, taking into account a cutoff of 14 % for 
the Ki-67 cell proliferation index. However, in the present 
study, the Ki-67 index was considered low for cases with 
value < 10% of immunopositivity and high for those with 
value ≥ 10%, as, in this population, this marker was scored 
as null (no immunostaining), low (≥ 10% of immunoposi-
tivity), or high (> 10% immunoreactive cells), based on the 
criteria adopted at the time of diagnosis38. This fact may 
explain the high percentage of tumors classified as luminal 
B HER2 negative in this study. 
The triple negative subtype, which in most studies 
shows frequency between 10% and 20%31,35,41,42, was found 
in almost one-quarter of the population (24.2%). This sub-
type showed higher percentages in younger patients, aged 
< 50 years (40%) and non-white (39.7%). These findings 
are similar to those observed in other studies that have per-
sistently shown the prevalence of triple negative tumors in 
younger black patients displaying more advanced disease at 
diagnosis and higher cell proliferation index35,43. Together 
with the triple negative subtype, the HER2 overexpression 
and luminal B-HER2 positive subgroups also showed, in 
this study, higher percentages of non-white patients with 
more advanced initial disease. Noteworthy is the fact that 
the subtypes that express HER2 are strongly in≥uenced 
by the proliferative state of the tumor, which tends to be 
higher in those subgroups44, which may explain their as-
sociation with tumors presenting more aggressive behavior. 
The predominant histological type was infiltrating 
ductal (73.5%), similar to the findings of other studies 
performed to assess survival in women with breast cancer 
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in Brazil45-48. The mean age at diagnosis was 57.4 years, a 
finding similar to that observed in a study by Blows et al.41, 
which observed a higher frequency of the disease among 
women aged 50 to 59 years for all subtypes, although 
slightly higher than the mean ages found in other Brazilian 
studies47,48, who were respectively 54.0 and 56.4 years. 
Kwan et al.49 found a higher frequency of younger women 
with the triple negative subtype, a finding similar to the 
present study, which identified a percentage of 35.8% of 
this subtype in those aged between 40 and 49 years. 
Characteristics Luminal A
Luminal 
B HER2 
negative
Luminal 
B HER2 
positive
HER2
Triple 
negative
Total cases 
and %
p-value
Health service# 0.03
Private 37 98 21 20 48 224  
Line % 16.5 43.8 9.4 8.9 21.4 100  
Col % 54.4 59.0 48.8 83.3 50.0 56.4  
Public 31 68 22 4 48 173  
Line % 17.9 39.3 12.7 2.3 27.7 100  
Col % 54.6 41.0 51.2 16.7 50.0 43.6  
Surgery# 0.2
Curative 53 126 37 16 82 314  
Line % 16.9 40.1 11.8 5.1 26.1 100  
Col % 80.3 79.2 90.2 72.7 86.3 82.0  
Diagnostic 13 33 4 6 13 69  
Line % 18.8 47.8 5.8 8.7 18.8 100  
Col % 19.7 20.8 9.8 23.7 13.7 18.0  
Hormone therapy#         0.0000
Use 60 139 33 1 4 237  
Line % 25.3 58.6 13.9 0.4 1.7 100  
Col % 88.2 84.8 76.7 4.2 4.3 60.3  
Non-use 8 25 10 23 90 156  
Line % 5.1 16.0 6.4 14.7 57.7 100  
Col % 11.8 15.2 23.3 95.8 95.7 39.7  
Chemotherapy*         0.0000
Use 25 94 28 17 74 238  
Line % 10.5 39.5 11.8 7.1 31.1 100  
Col % 36.8 57.3 65.1 70.8 78.7 60.6  
Non-use 43 70 15 7 20 155  
Line % 27.7 45.2 9.7 4.5 12.9 100  
Col % 63.2 42.7 34.9 29.2 21.3 39.4  
Radiotherapy#         0.01
Use 57 116 36 19 69 297  
Line % 19.2 39.1 12.1 6.4 23.2 100  
Col % 86.4 73.4 90.0 95.0 83.1 80.9  
Non-use 9 42 4 1 14 70  
Line % 12.9 60.0 5.7 1.4 20.0 100  
Col % 13.6 26.6 10.0 5.0 16.1 19.1  
#Fisher’s Test; *χ2 Test.Total cases of each variable may differ due to the occurrence of ignored data.
Table 3 – Distribution of characteristics related to use of the public health services and treatment, according to subtypes of 
breast cancer classiﬁed by immunohistochemical analysis
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Most women were white (80.7%), with a higher fre-
quency among all subtypes. The black race is, in general, 
associated with worse prognosis when compared to other 
ethnic-racial groups50. A higher percentage of non-white 
with the triple negative subtype (39.7%) was found, which 
was related with more advanced initial disease and may 
reect, for these women, late diagnosis and di cult access 
to healthcare services. This finding may also represent a 
greater severity of these tumors due to their phenotype. 
However, the miscegenation of the Brazilian population 
should be taken into account (when compared to the U.S. 
population, for example), which complicates the precise 
characterization of this variable and, also, the possibility of 
misclassification of ethnicity in this study, as this informa-
tion was collected based on the perceptions of the profes-
sionals responsible for filling out the initial medical file.
It should be noted that in this population, which had 
all the markers selected for the study, 56.4% of women 
were treated by the private health sector. Therefore, it is a 
distinct population, regarding access to healthcare, in re-
lation to the Brazilian population. For HER2 overexpres-
sion, luminal B HER2 negative, and luminal A subtypes, 
most patients were treated at private healthcare services 
(83.3%, 59.0%, and 54.4%, respectively). Also notewor-
thy is the fact that among the patients who were treated 
at public health services, 5.6% had private healthcare 
insurance.  
A higher frequency of tumors < 2.0 cm (65.8%) and 
with no lymph node involvement (62.8%) was observed 
in patients treated at the private healthcare services, while 
the highest percentages of tumors > 2.0 cm and positive 
lymph nodes were identified in the public healthcare 
services (66.3% and 50.6% respectively, p = 0.003 and 
p = 0.002). In a survival study carried out by Guerra et al.51 
in a hospital cohort of women with breast cancer treated in 
the same city, there was a higher frequency of patients who 
had private healthcare insurance and had been treated at 
the public healthcare services (37.7%). However, the lat-
ter study showed an increased risk of death due to breast 
cancer in women with no private healthcare, which was 
related to later diagnosis and poor access to specific treat-
ment, in accordance with what was observed in the pres-
ent cohort regarding the type of the health services used.
Developing countries present lower incidence of over-
all cancer rates, (considering all locations), approximately 
half of that observed in developed countries. However, 
the mortality rates tend to be similar in these countries3, 
which can be a result of a higher death risk in develop-
ing countries, probably due to a combination of risk fac-
tors in these countries, such as diagnosis at a later stage 
of the disease, and limited access to diagnostic methods 
and standard treatment3,10. Although the socioeconomic 
status of the study population can be considered high in 
relation to the Brazilian population in general, tumors 
> 2.0 cm were predominant, with positive axillary nodes, 
reinforcing the need for public health policies aimed at 
consolidating the national screening program for breast 
cancer, especially for the group of women considered at 
higher risk, as well as ensuring timely treatment for diag-
nosed patients.  
Noteworthy is the fact that the high percentage of the 
luminal B HER2 negative subtype in this cohort may be 
related to the probable inclusion of an unknown percent-
age of tumors that should be classified as luminal A, ac-
cording to the classification prior to that of the St. Gallen 
Consensus (2011). Thus, using the classification proposed 
by the Consensus in this study may have favored the com-
bination, in the luminal B HER2 negative category, of the 
luminal A and B subtypes, with the latter being a subtype 
oen associated with a more favorable outcome. This 
possibility should be taken into account when interpret-
ing the differences observed in relation to the luminal B 
HER2 negative subtype.  
When interpreting the findings regarding the distri-
bution of metastases in the study population, however, 
the possibility of metastasis underestimation at diagnosis 
must be taken into account, as staging tests could not be 
verified for all cases. In this sense, it is also worth men-
tioning that there was no significant difference in the 
distribution of metastases (at diagnosis and during the 
course of the disease) in the study population, according 
to the nature of the health service (public versus private).
Finally, it must be considered that in this study, immu-
nohistochemical data were obtained from medical reports 
contained in patient files and examination reviews were 
not carried out, which can have an impact on the reli-
ability of this information. However, it is worth mention-
ing that all pathological anatomy services responsible for 
the immunohistochemical panel assessment of the study 
population had acknowledged technical quality, were ac-
credited and provided concomitant services to public and 
private institutions. These findings reinforce data quality 
and minimize a possible differential error related to the 
nature of health services. 
This study allowed the characterization of immuno-
histochemical subgroups in patients with breast cancer 
treated at a referral center for cancer care in Southeast-
ern Brazil, using a recently updated immunohistochemi-
cal classification30. It also allowed the assessment of sub-
group distribution in relation to the main clinical and 
pathological characteristics and those related to the use of 
healthcare services. In this sense, it is noteworthy that the 
association between the histological diagnosis and immu-
nohistochemical technique can help to determine the phe-
notypic profile of breast cancer, aiming to guide treatment 
and, consequently, to improve the therapeutic response.
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Therefore, the need for better use of available informa-
tion on health services responsible for the care of cancer 
patients in Brazil becomes clear, aiming to produce knowl-
edge that can best assist the effort to manage this public 
health problem in Brazil.
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